Comparison of SVT patients with and without latent MPD and the JAK2-V617F mutation
. | All patients . | . | Patients with latent MPD . | . | ||
|---|---|---|---|---|---|---|
. | No evidence of MPD . | Latent MPD . | JAK2-V617F negative . | JAK2-V617F positive . | ||
| No. patients | 28 | 17 | 3 | 14 | ||
| Site of thrombosis, hepatic veins/portal venous system | 4/24 | 2/15 | 0/3 | 2/12 | ||
| Sex, male/female | 15/13 | 9/8 | 3/0 | 6/8 | ||
| Age, y | 51 ± 16 | 40 ± 11 | 40 ± 18 | 42 ± 11 | ||
| JAK2-V617F, copies/100 ABL | 0 | 86 ± 91 | 0 | 110 ± 89 | ||
| JAK2-WT, copies/100 ABL | 774 ± 889 | 491 ± 476 | 222 ± 155 | 564 ± 511 | ||
| Hematocrit | 0.380 ± 0.57 | 0.396 ± 0.53 | 0.383 ± 0.42 | 0.399 ± 0.55 | ||
| Hemoglobin level, g/L | 127 ± 20 | 130 ± 15 | 131 ± 16 | 129 ± 16 | ||
| Platelet count, × 109/L | 239 ± 100 | 251 ± 123 | 237 ± 122 | 255 ± 128 | ||
| Leukocyte count, × 109/L | 8.0 ± 5.4 | 7.8 ± 5.0 | 7.2 ± 2.9 | 7.9 ± 5.4 | ||
| PRV-1/ABL, CT ratio | 0.962 ± 0.084 | 0.875 ± 0.120* | 1.032 ± 0.024 | 0.843 ± 0.106† | ||
| EPO level, IU/L | 24.5 ± 31.5 | 9.0 ± 8.9 | 6.7 ± 0.4 | 9.6 ± 9.9 | ||
| EECs, patients positive, % | 0 | 12 | 0 | 14 | ||
| EMCs, patients positive, % | 0 | 87 | 100 | 85 | ||
| Histology in favor of MPD, no./no. total | 0/10 | 11/12 | 2/2 | 9/10 | ||
| Inherited thrombophilia, no./no. total | 5/19 | 3/9‡ | 0/2 | 3/9 | ||
| Protein C deficiency | 2 | 0 | 0 | 0 | ||
| Protein S deficiency | 1 | 3 | 0 | 3 | ||
| Heterozygous factor V Leiden mutation | 1 | 1 | 0 | 1 | ||
| Heterozygous factor II G20210A | 1 | 0 | 0 | 0 | ||
| Acquired thrombophilia | 8 | 0 | 0 | 0 | ||
| Lupus anticoagulant | 2 | 0 | 0 | 0 | ||
| Pregnancy | 1 | 0 | 0 | 0 | ||
| Hepatocarcinoma | 1 | 0 | 0 | 0 | ||
| Cirrhosis | 2 | 0 | 0 | 0 | ||
| Severe acute pancreatitis | 1 | 0 | 0 | 0 | ||
| Abdominal sepsis | 1 | 0 | 0 | 0 | ||
. | All patients . | . | Patients with latent MPD . | . | ||
|---|---|---|---|---|---|---|
. | No evidence of MPD . | Latent MPD . | JAK2-V617F negative . | JAK2-V617F positive . | ||
| No. patients | 28 | 17 | 3 | 14 | ||
| Site of thrombosis, hepatic veins/portal venous system | 4/24 | 2/15 | 0/3 | 2/12 | ||
| Sex, male/female | 15/13 | 9/8 | 3/0 | 6/8 | ||
| Age, y | 51 ± 16 | 40 ± 11 | 40 ± 18 | 42 ± 11 | ||
| JAK2-V617F, copies/100 ABL | 0 | 86 ± 91 | 0 | 110 ± 89 | ||
| JAK2-WT, copies/100 ABL | 774 ± 889 | 491 ± 476 | 222 ± 155 | 564 ± 511 | ||
| Hematocrit | 0.380 ± 0.57 | 0.396 ± 0.53 | 0.383 ± 0.42 | 0.399 ± 0.55 | ||
| Hemoglobin level, g/L | 127 ± 20 | 130 ± 15 | 131 ± 16 | 129 ± 16 | ||
| Platelet count, × 109/L | 239 ± 100 | 251 ± 123 | 237 ± 122 | 255 ± 128 | ||
| Leukocyte count, × 109/L | 8.0 ± 5.4 | 7.8 ± 5.0 | 7.2 ± 2.9 | 7.9 ± 5.4 | ||
| PRV-1/ABL, CT ratio | 0.962 ± 0.084 | 0.875 ± 0.120* | 1.032 ± 0.024 | 0.843 ± 0.106† | ||
| EPO level, IU/L | 24.5 ± 31.5 | 9.0 ± 8.9 | 6.7 ± 0.4 | 9.6 ± 9.9 | ||
| EECs, patients positive, % | 0 | 12 | 0 | 14 | ||
| EMCs, patients positive, % | 0 | 87 | 100 | 85 | ||
| Histology in favor of MPD, no./no. total | 0/10 | 11/12 | 2/2 | 9/10 | ||
| Inherited thrombophilia, no./no. total | 5/19 | 3/9‡ | 0/2 | 3/9 | ||
| Protein C deficiency | 2 | 0 | 0 | 0 | ||
| Protein S deficiency | 1 | 3 | 0 | 3 | ||
| Heterozygous factor V Leiden mutation | 1 | 1 | 0 | 1 | ||
| Heterozygous factor II G20210A | 1 | 0 | 0 | 0 | ||
| Acquired thrombophilia | 8 | 0 | 0 | 0 | ||
| Lupus anticoagulant | 2 | 0 | 0 | 0 | ||
| Pregnancy | 1 | 0 | 0 | 0 | ||
| Hepatocarcinoma | 1 | 0 | 0 | 0 | ||
| Cirrhosis | 2 | 0 | 0 | 0 | ||
| Severe acute pancreatitis | 1 | 0 | 0 | 0 | ||
| Abdominal sepsis | 1 | 0 | 0 | 0 | ||
Patients with no evidence of MPD are patients who did not carry the JAK2-V617F mutation and did not form EMC/EEC in vitro. Patients with latent MPD are patients who carried the JAK2-V617F mutation and/or formed EMCs/EECs in vitro. Unless stated otherwise, results were expressed as means ± SD.
CT indicates cycle threshold.
P = .028 compared with patients with no evidence of MPD.
P = .009 compared with patients negative for JAK2-V617F, Mann-Whitney rank sum test.
One patient had 2 causes of inherited thrombophilia.